Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis

Clinical Positron Imaging (Netherlands)

Volumn 2, Issue 3, 1999, Pages 159-171

  Larson, Steven M ^a   Erdi, Yusuf ^a   Akhurst, Timothy ^a   Mazumdar, Madhu ^a   Macapinlac, Homer A ^a   Finn, Ronald D ^a   Casilla, Cecille ^a   Fazzari, Melissa ^a   Srivastava, Neil ^a   Yeung, Henry W D ^a   Humm, John L ^a   Guillem, Jose ^a   Downey, Robert ^a   Karpeh, Martin ^a   Cohen, Alfred E ^a   Ginsberg, Robert ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

FDG; Glycolysis; PET; Tumor Metabolism; Tumor Response

Indexed keywords

EID: 0000827344     PISSN: 10950397     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1095-0397(99)00016-3     Document Type: Article

References (47)

1. R.L. Wahl Clinical oncology update The emerging role of positron emission tomography Prin. Prac. Oncol. 11 1997 1
2. R.T. Heelan S.M. Larson Imaging of thoracic neoplasms J. Aisner R. Arriagada M.R. Green N. Martini M.C. Perry Comprehensive textbook of thoracic oncology 1996 Williams & Wilkins Baltimore
3. R.J. Gralla Preoperative and adjuvant chemotherapy in non-small cell lung cancer Semin. Oncol. 15 Suppl 1988 8 12
4. M.E. Phelps S.R. Cherry The changing design of positron imaging systems Clin. Pos. Imag. 1 1998 31 46
5. V.W. Rusch K.S. Albain J.J. Crowley Neo-adjuvant therapy A novel and effective treatment for state IIIb non-small cell lung cancer Ann. Thorac. Surg. 58 1994 290 295
6. V. Rusch D. Klimstra E. Vendatraman Aberrant p53 expression predicts clinical resistance to Cisplatin-based chemotherapy in locally advanced non-small cell lung cancer Cancer Res. 55 1995 5038 5042
7. T.R. DeGrado T.G. Turkington J.J. Williams C.W. Stearns J.M. Hoffman R.E. Coleman Performance characteristics of a whole-body PET scanner J. Nucl. Med. 35 1994 1398 1406
8. Y.E. Erdi O. Mawlawi S.M. Larson Segmentation of lung lesion volume by adaptive PET image thresholding Cancer 80 Suppl 12 1997 2505 2509
9. M.E. Phelps E.J. Hoffman C. Selin Investigation of [F18]-fluoro-2-deoxyglucose for the measurement of myocardial glucose metabolism J. Nucl. Med. 19 1978 1311 1319
10. H.E. Skipper F.M. Schabel Jr. W.S. Wilcox Experimental evaluation of potential anticancer agents XII. On the criteria and kinetics associated with “curability” of experimental leukemia Cancer Chemother. Rep. 35 1964 1 111
11. K. Higashi A.C. Clavo R.L. Wahl Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiate thymidine uptake J. Nucl. Med. 34 1993 414 419
12. R.S. Brown J.Y. Leung S.J. Fisher Intratumoral distribution of tritiated FDG in breast carcinoma Correlation between glut-1 expression and FDG uptake J. Nucl. Med. 37 1996 1042 1047
13. K. Herholz U. Pietrzyk J. Voges Correlation of glucose consumption and tumor cell density in astrocytomas. A stereotactic PET study J. Neurosurg. 79 1993 853 858
14. P. Som H.L. Atkins K. Bandoypadhyay A fluorinated glucose analog, 2-fluoro-2-deoxy–D-glucose(F-18) Non-toxic tracer for rapid tumor detection J. Nucl. Med. 21 1980 670 675
15. S.M. Larson Z. Grunbaum J.S. Rasey Positron imaging feasibility studies I. Selective tumor concentration of [H-3] thymidine, [H-3] uridine, and [C-14]-2-deoxy-glucose, based on the characteristic metabolism of malignancy Radiology 134 1980 771 773
16. S.M. Larson P.L. Weiden Z. Grunbaum Positron imaging feasibility studies. II. Characteristics of 2-deoxyglucose uptake in rodent and canine neoplasms. Concise communication J. Nucl. Med. 22 1981 875 879
17. G. Weber Enzymology of cancer cells N. Eng. J. Med. 296 1976 541 551
18. G. Di Chiro R.L. DeLaPaz R.A. Brooks Glucose utilization of cerebral gliomas measured by F18-fluorodeoxyglucose and positron emission tomography Neurology 32 1982 1323
19. G. Di Chiro M.J. Fulham Virchow's shackles Can PET-FDG challenge tumor histology? Am. J. Neuroradiol. 14 1993 524 527
20. G. Di Chiro Which PET radiopharmaceutical for brain tumors? J. Nucl. Med. 32 1991 1346 1348
21. G. Di Chiro E. Oldfield D.C. Wright Cerebral necrosis after radiotherapy or intra-arterial chemotherapy for brain tumors PET and neuropathologic studies Am. J. Roentgen. 150 1988 189 197
22. T.L. Francavilla R.S. Miletich G. Di Chiro Positron emission tomography in the detection of malignant degen- eration of low-grade gliomas Neurosurgery 24 1989 1 5
23. G. Di Chiro J. Hatazawa D.A. Katz Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence A PET study Radiology 164 1987 521 526
24. J.F. Petronas G. Di Chiro C. Kufta Prediction of survival in glioma patients by means of positron emission tomography (PET) J. Neurosurg. 62 1985 816 822
25. F.G. Barker S.M. Chang P.E. Valk T.R. Pounds M.D. Prados 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma Cancer 79 1997 115 126
26. T. Schifter J.M. Hoffman M.W. Hanson Serial FDG-PET studies in the prediction of survival in patients with primary brain tumors J. Comput. Assist. Tomogr. 17 1993 509 561
27. P.E. Valk T.F. Budinger V.A. Levin P. Silver P.H. Gutin W.K. Doyle PET of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome J. Neurosurg. 69 1988 830 838
28. D. Delbeke C. Meyerowitz R.L. Lapidus Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET Radiology 195 1995 47 52
29. Y. Yonekura R.S. Benua A.B. Brill Increased accumulation of 2-deoxy-2-[F-18]fluoro-D-glucose in liver metastases from colon carcinoma J. Nucl. Med. 23 1982 1133 1137
30. L. Sokoloff M. Reivich C. Kennedy The [C14] deoxyglucose method for the measurement of local cerebral glucose utilization Theory procedure and normal values in the conscious and anesthetized rat J. Neurochem. 28 1977 897 916
31. M. Reivich A. Alavi A. Wolf Glucose metabolic rate kinetic model parameter determination in humans Lump constant and rate constant for (F-18) fluorodeoxyglucose J. Cereb. Blood Flow Metab. 5 1985 179 192
32. M.E. Phelps S.C. Huang E.S. Hoffman C. Selin L. Sokoloff D.E. Kuhl Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18) 2-fluoro-deoxy-D-glucose Validation of a method Ann. Neurol. 6 1979 371 388
33. A.M. Spence M. Muzi M.M. Graham Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]glucose and FDG Analysis of the FDG lumped constant J. Nucl. Med. 39 1998 440 448
34. K. Kubota T. Matsuzawa M. Ito Lung tumor imaging by positron emission tomography using C-11 L-methionine J. Nucl. Med. 26 1985 37 42
35. R.L. Wahl Positron emission tomography applications to oncology I.P.C. Murray P.J. Ell Nuclear medicine in clinical diagnosis and treatment 1994 Churchill Livingstone London
36. J.F. Eary D.A. Mankoff Tumor metabolic rates in sarcoma using FDG PET J. Nucl. Med. 39 1998 250 254
37. V.J. Lowe F.G. Duhaylongsod E.F. Patz Pulmonary abnormalities and PET Data analysis A retrospective study Radiology 202 1997 435 439
38. J.F. Eary E.U. Conrad J.D. Bruckner Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma Clin. Cancer Res. 4 1998 1215 1220
39. K.A. Kern A. Brunetti J.A. Norton Metabolic imaging of human extremity musculoskeletal tumors by PET J. Nucl. Med. 29 1988 181 186
40. F.G. Duhaylongsod V.J. Lowe E.F.J. Patz A.L. Vaughn R.E. Cleman W.G. Wolfe Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography Ann. Thorac. Surg. 60 1995 1348 1352
41. T. Fukunaga S. Okazumi Y. Koide K. Isono K. Imazeki Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET J. Nucl. Med. 39 1998 1002 1007
42. H. Minn M. Lapela P.J. Klemi Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer J. Nucl. Med. 38 1997 1907 1911
43. E.F. Patz V.J. Lowe J.M. Hoffman Focal pulmonary abnormalities Evaluation with F-18 fluorodeoxyglucose PET scanning Radiology 188 1993 487 490
44. M. Findlay H. Young D. Cunningham Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases correlation with tumor response to fluorouracil J. Clin. Oncol. 14 1996 700 708
45. R.L. Wahl K. Zasadny M. Helvie G.D. Hutchins B. Weber R. Cody Metabolic monitoring of breast cancer chemo hormonotherapy using positron emission tomography Initial evaluation J. Clin. Oncol. 11 1993 2101 2111
46. W. Romer A.R. Hanauske S. Ziegler Positron emission tomography in non-Hodgkin's lymphoma Assessment of chemotherapy with fluorodeoxyglucose Blood 91 1998 4464 4471
47. G.J. Hunter L.M. Hamberg N.M. Alpert N.C. Coi A.J. Fischman Simplified measurement of deoxyglucose utilization rate J. Nucl. Med. 37 1996 950 955